^
    Back
    Association details:
    Biomarker:Chr del(6q)(q15)
    Cancer:Follicular Lymphoma
    Drug:Copiktra (duvelisib) (PI3Kδ inhibitor, PI3Kγ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMOTM Clinical Trial in iNHL

    Published date:
    11/01/2018
    Excerpt:
    In the Phase 2 DYNAMO trial of duvelisib monotherapy for relapsed/refractory iNHL, the FL subgroup (n=83)…patients with del(6q13-q15) or del(6q23.3-q24.1) had an mPFS of 11.8 mo (n=17) compared to 8.3 mo (n=23) for those without either deletion, with an ORR of 52.9% vs 43.5%, respectively.
    DOI:
    10.1182/blood-2018-99-117903
    Trial ID:
    DYNAMO